AdhexPharma ranked 171st on Europe’s Long-Term Growth Champions by the Financial Times

We are thrilled to announce that AdhexPharma has achieved a remarkable milestone by being ranked 171st in the Financial Times' inaugural list of Europe’s Long-Term Growth Champions. This prestigious list, which highlights the top 300 companies across Europe, recognizes businesses that have demonstrated exceptional and consistent growth over the past decade.

Furthermore, we are proud to rank 6th in the highly competitive category of Pharmaceuticals and Cosmetics, a testament to our significant impact and leadership within the industry. This recognition underscores our unwavering commitment to sustained growth and excellence as we navigate the complex and ever-evolving challenges of the global market. It reflects our dedication to innovation, quality, and the relentless pursuit of excellence, which have been the driving forces behind our success.

About the Financial Times’ Long-Term Growth Champions List,

The Financial Times, in collaboration with Statista, introduced the Long-Term Growth Champions list to spotlight 300 European companies that have achieved remarkable, consistent sales growth over the past decade. This inaugural ranking evaluates businesses based on their compound annual growth rates (CAGR) and underscores their ability to thrive amid significant economic shifts.
The list celebrates companies that have not only weathered global financial crises but have also navigated recent geopolitical disruptions with agility and resilience.
Being featured in this ranking is a testament to an organization’s ability to innovate, adapt, and lead in its sector.

Oral Films and Transdermal Patches, The Future of Medication ? 

In an era where convenience and efficiency are paramount, oral films and transdermal patches represent the future of medication. These innovative delivery systems offer solutions that align with modern healthcare needs, addressing the growing demand for more accessible and user-friendly treatment options.
These advanced delivery systems provide numerous advantages over traditional methods, including improved patient compliance, precise dosing, and reduced side effects, which are crucial in enhancing the overall effectiveness of medical treatments.

• Oral films: These dissolve quickly in the mouth, eliminating the need for water and making them ideal for patients with swallowing difficulties, such as the elderly or those with certain medical conditions. This ease of administration not only improves the patient experience but also ensures that medication is taken as prescribed, thereby increasing its efficacy.
• Transdermal patches: These provide a steady release of medication through the skin, maintaining consistent therapeutic levels and reducing the risk of gastrointestinal complications associated with oral medications. They are particularly beneficial for patients who require long-term medication management, as it reduces the frequency of dosing and enhances adherence to treatment regimens.

As the pharmaceutical industry continues to evolve, these technologies are poised to revolutionize how we administer and experience medication, paving the way for more personalized and patient-friendly treatment options that cater to the diverse needs of patients across the globe. By integrating these innovative delivery systems into mainstream healthcare, we can anticipate a future where medication is not only more effective but also more aligned with the lifestyles and preferences of patients, ultimately leading to better health outcomes and improved quality of life.

Building Momentum for the Future,

While this accomplishment marks a significant milestone in our journey, it also serves as a catalyst that fuels our drive to continue striving for excellence in every aspect of our operations. This recognition not only validates our past efforts but also inspires us to push the boundaries of innovation and quality in the pharmaceutical industry. Our dedication to excellence drives us to explore and develop cutting-edge solutions, and set new standards in the industry, ensuring that we remain at the forefront of pharmaceutical advancements.

Since its founding in 2008, AdhexPharma has steadily built a reputation for quality and innovation. We currently manufacture eight approved products, including oral films and transdermal patches, with an impressive annual output of more than 100 million units per year. Our 25% annual growth rate over the past decade reflects our commitment to meeting the evolving needs of the healthcare sector.

To support this ongoing expansion and to accommodate future projects, we are excited to announce the construction of a new state-of-the-art 8,000m²  facility, set for completion by the end of 2025. This new hub of pharmaceutical excellence in France will feature advanced production units, expansive storage facilities, cutting-edge quality control and R&D laboratories, and modern administrative offices.

This strategic development will not only ensure our continued compliance with regulatory standards but also position us to welcome new projects and innovations, further solidifying our role as a leader in the pharmaceutical industry.